Accuracy of percentage of signal intensity recovery and relative cerebral blood volume derived from dynamic susceptibility-weighted, contrast-enhanced MRI in the preoperative diagnosis of cerebral tumours
暂无分享,去创建一个
[1] K A Smitha,et al. Relative percentage signal intensity recovery of perfusion metrics—an efficient tool for differentiating grades of glioma. , 2015, The British journal of radiology.
[2] K. Lovblad,et al. State-of-the-art MRI techniques in neuroradiology: principles, pitfalls, and clinical applications , 2015, Neuroradiology.
[3] M. Muti,et al. High- and low-grade glioma differentiation: the role of percentage signal recovery evaluation in MR dynamic susceptibility contrast imaging , 2015, La radiologia medica.
[4] M. Essig,et al. Principles of T2*‐weighted dynamic susceptibility contrast MRI technique in brain tumor imaging , 2015, Journal of magnetic resonance imaging : JMRI.
[5] Z. Xing,et al. Differentiation of Primary Central Nervous System Lymphomas from High-Grade Gliomas by rCBV and Percentage of Signal Intensity Recovery Derived from Dynamic Susceptibility-Weighted Contrast-Enhanced Perfusion MR Imaging , 2014, Clinical Neuroradiology.
[6] Girolamo Crisi,et al. Differences in Dynamic Susceptibility Contrast MR Perfusion Maps Generated by Different Methods Implemented in Commercial Software , 2014, Journal of computer assisted tomography.
[7] W. Mueller,et al. Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma. , 2014, Neuro-oncology.
[8] G. Tedeschi,et al. Recurrent glioblastoma multiforme versus radiation injury: a multiparametric 3-T MR approach , 2014, La radiologia medica.
[9] R. Young,et al. Role of MRI perfusion in improving the treatment of brain tumors , 2013 .
[10] J. Boxerman,et al. The Effect of Pulse Sequence Parameters and Contrast Agent Dose on Percentage Signal Recovery in DSC-MRI: Implications for Clinical Applications , 2013, American Journal of Neuroradiology.
[11] S. Ng,et al. Differentiation of Primary Central Nervous System Lymphomas and Glioblastomas: Comparisons of Diagnostic Performance of Dynamic Susceptibility Contrast-Enhanced Perfusion MR Imaging without and with Contrast-Leakage Correction , 2013, American Journal of Neuroradiology.
[12] A. Holodny,et al. Comparison of the effectiveness of MRI perfusion and fluorine-18 FDG PET-CT for differentiating radiation injury from viable brain tumor: a preliminary retrospective analysis with pathologic correlation in all patients. , 2013, Clinical imaging.
[13] W. Rooney,et al. Pseudoprogression of glioblastoma after chemo- and radiation therapy: diagnosis by using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging with ferumoxytol versus gadoteridol and correlation with survival. , 2013, Radiology.
[14] Max Wintermark,et al. Perfusion MRI: the five most frequently asked clinical questions. , 2013, AJR. American journal of roentgenology.
[15] Guy Cosnard,et al. Multiparametric magnetic resonance imaging to differentiate high-grade gliomas and brain metastases. , 2012, Journal of neuroradiology. Journal de neuroradiologie.
[16] K. Aldape,et al. Initial treatment patterns over time for anaplastic oligodendroglial tumors. , 2012, Neuro-oncology.
[17] Y. Yamada,et al. Radiation necrosis following treatment of high grade glioma—a review of the literature and current understanding , 2012, Acta Neurochirurgica.
[18] D. Haynor,et al. Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma recurrence from posttreatment effects , 2012, Journal of magnetic resonance imaging : JMRI.
[19] A. Sorensen,et al. Pseudoprogression and Pseudoresponse: Imaging Challenges in the Assessment of Posttreatment Glioma , 2011, American Journal of Neuroradiology.
[20] Kim Mouridsen,et al. T1- and T*2-Dominant Extravasation Correction in DSC-MRI: Part I—Theoretical Considerations and Implications for Assessment of Tumor Hemodynamic Properties , 2011, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[21] Sean S. Park,et al. Differentiation between intra-axial metastatic tumor progression and radiation injury following fractionated radiation therapy or stereotactic radiosurgery using MR spectroscopy, perfusion MR imaging or volume progression modeling. , 2011, Magnetic resonance imaging.
[22] S Ekholm,et al. Percentage Signal Recovery Derived from MR Dynamic Susceptibility Contrast Imaging Is Useful to Differentiate Common Enhancing Malignant Lesions of the Brain , 2011, American Journal of Neuroradiology.
[23] A. Server,et al. Measurements of diagnostic examination performance and correlation analysis using microvascular leakage, cerebral blood volume, and blood flow derived from 3T dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging in glial tumor grading , 2011, Neuroradiology.
[24] D. Kong,et al. Diagnostic Dilemma of Pseudoprogression in the Treatment of Newly Diagnosed Glioblastomas: The Role of Assessing Relative Cerebral Blood Flow Volume and Oxygen-6-Methylguanine-DNA Methyltransferase Promoter Methylation Status , 2011, American Journal of Neuroradiology.
[25] Jonathan R. Young,et al. Advances in MRI Assessment of Gliomas and Response to Anti-VEGF Therapy , 2011, Current neurology and neuroscience reports.
[26] D. Tampieri,et al. Imaging in Primary Central Nervous System Lymphoma , 2010, The neuroradiology journal.
[27] Sanjay Sharma. LEVELS OF EVIDENCE , 2007 .
[28] M. Endo,et al. Perfusion weighted magnetic resonance imaging to distinguish the recurrence of metastatic brain tumors from radiation necrosis after stereotactic radiosurgery , 2010, Journal of Neuro-Oncology.
[29] M. J. van den Bent,et al. Pseudoprogression and pseudoresponse in the treatment of gliomas , 2009, Current opinion in neurology.
[30] M. Berger,et al. Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. , 2009, Radiology.
[31] P. Cassoni,et al. Role of diffusion- and perfusion-weighted MR imaging for brain tumour characterisation , 2009, La radiologia medica.
[32] J E Heiserman,et al. Relative Cerebral Blood Volume Values to Differentiate High-Grade Glioma Recurrence from Posttreatment Radiation Effect: Direct Correlation between Image-Guided Tissue Histopathology and Localized Dynamic Susceptibility-Weighted Contrast-Enhanced Perfusion MR Imaging Measurements , 2009, American Journal of Neuroradiology.
[33] B. Tang,et al. Differentiation of primary central nervous system lymphoma and high-grade glioma with dynamic susceptibility contrast-enhanced perfusion magnetic resonance imaging , 2009, Acta radiologica.
[34] M R Segal,et al. Distinguishing Recurrent Intra-Axial Metastatic Tumor from Radiation Necrosis Following Gamma Knife Radiosurgery Using Dynamic Susceptibility-Weighted Contrast-Enhanced Perfusion MR Imaging , 2008, American Journal of Neuroradiology.
[35] K. Schmainda,et al. Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors. , 2008, Radiology.
[36] A Gregory Sorensen,et al. Perfusion MR imaging: moving forward. , 2008, Radiology.
[37] T. Hirai,et al. Prognostic Value of Perfusion MR Imaging of High-Grade Astrocytomas: Long-Term Follow-Up Study , 2008, American Journal of Neuroradiology.
[38] Gordon H Guyatt,et al. GrADe : what is “ quality of evidence ” and why is it important to clinicians ? rATING quALITY of evIDeNCe AND STreNGTH of reCommeNDATIoNS , 2022 .
[39] A. Waldman,et al. Low-grade gliomas: do changes in rCBV measurements at longitudinal perfusion-weighted MR imaging predict malignant transformation? , 2008, Radiology.
[40] C. Avezaat,et al. Safety and efficacy of frameless and frame-based intracranial biopsy techniques , 2008, Acta Neurochirurgica.
[41] B. Scheithauer,et al. The 2007 WHO Classification of Tumours of the Central Nervous System , 2007, Acta Neuropathologica.
[42] D. Louis,et al. Survey of treatment recommendations for anaplastic oligodendroglioma. , 2007, Neuro-oncology.
[43] M. Berger,et al. Differentiation of Glioblastoma Multiforme and Single Brain Metastasis by Peak Height and Percentage of Signal Intensity Recovery Derived from Dynamic Susceptibility-Weighted Contrast-Enhanced Perfusion MR Imaging , 2007, American Journal of Neuroradiology.
[44] R M Weisskoff,et al. Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. , 2006, AJNR. American journal of neuroradiology.
[45] A. Jackson,et al. Do cerebral blood volume and contrast transfer coefficient predict prognosis in human glioma? , 2006, AJNR. American journal of neuroradiology.
[46] J. Guyotat,et al. Clinical relevance of diffusion and perfusion magnetic resonance imaging in assessing intra-axial brain tumors , 2006, Neuroradiology.
[47] Glyn Johnson,et al. Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging--prediction of patient clinical response. , 2006, Radiology.
[48] Karl Herholz,et al. Imaging in neurooncology , 2005, NeuroRX.
[49] I. Ercan,et al. High-grade and low-grade gliomas: differentiation by using perfusion MR imaging. , 2005, Clinical radiology.
[50] Nancy J Fischbein,et al. Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging. , 2005, AJNR. American journal of neuroradiology.
[51] Michael H Lev,et al. Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. , 2004, AJNR. American journal of neuroradiology.
[52] Glyn Johnson,et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. , 2003, AJNR. American journal of neuroradiology.
[53] V. Tronnier,et al. Distinguishing of primary cerebral lymphoma from high-grade glioma with perfusion-weighted magnetic resonance imaging , 2003, Neuroscience Letters.
[54] Glyn Johnson,et al. Relative cerebral blood volume measurements in intracranial mass lesions: interobserver and intraobserver reproducibility study. , 2002, Radiology.
[55] Oxford Centre for Evidence-based Medicine Levels of Evidence (January 2001) , 2014 .
[56] S. Ekholm,et al. Correlation between progression free survival and dynamic susceptibility contrast MRI perfusion in WHO grade III glioma subtypes , 2013, Journal of Neuro-Oncology.
[57] M. Essig,et al. Perfusion MRI: the five most frequently asked technical questions. , 2013, AJR. American journal of roentgenology.
[58] Timothy A. Chan,et al. MRI perfusion in determining pseudoprogression in patients with glioblastoma. , 2013, Clinical imaging.
[59] S. Paek,et al. Stereotactic biopsy for intracranial lesions: reliability and its impact on the planning of treatment , 2003, Acta Neurochirurgica.
[60] R. Barnard,et al. The classification of tumours of the central nervous system. , 1982, Neuropathology and applied neurobiology.